Loading
A phase 3 trial of Gamma Knife in Pituitary tumours, run by Samsung Medical Center, with a status the registry has not verified recently.
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma is a phase 3 interventional study registered as NCT03439709 by Samsung Medical Center, with 90 participants planned, started 2018-03-01 and due to reach its primary completion in 2022-06-30. Interventions recorded: Gamma knife radiosurgery, Lanreotide 60Mg Solution for Injection. Conditions recorded: Acromegaly Due to Pituitary Adenoma.
Linked to the technology Gamma Knife because the registry names it ("gamma knife") among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.
Shares Gamma Knife and the tag pipeline.
Shares Gamma Knife and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.
Shares Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma and the tag pipeline.